Characteristics of fever in patients with COVID-19 at presentation and after initiation of treatment

Main Article Content

Ali Fawzi Abd alsahib
Doaa Faris Jabaz
Akeel M. Hamza
Anwar Jasib Almzaiel


Characteristics, Fever, COVID-19


Background: COVID-19 infection manifests itself in a variety of ways, from asymptomatic/mild symptoms to death or serious illness. Coughing, shortness of breath, and fever are all common symptoms. Other symptoms include weakness, muscle discomfort, lethargy, sore throat, breathing problems, and loss of smell and/or taste. COVID-19 is diagnosed utilizing clinical indicators, CT scans or chest x-rays, serological tests, and molecular diagnostics of the viral genome using RT-PCR.

Aim of the study: In the current study we aimed to shed light on the duration of fever, the most important symptom of the disease, and its association with other patients’ characteristics.

Patients and methods: The current cross-sectional study was conducted in Iraq's Al-Diwaniyah Province, which is located in the Mid-Euphrates region. The study included 99 COVID-19 cases, 50 males and 49 females ranging in age from 16 to 81 years. Age, gender, WBC count, lymphocyte percent, lung involvement assessed by CT-scan, duration of fever at time of presentation, and duration until fever subsides following initiation of treatment were the main variables studied in the current study, in addition to the presence of chronic medical illnesses such as diabetes mellitus, systemic hypertension, asthma, and pulmonary tuberculosis.

Results: The mean age of all enrolled patients was 50.38 ±16.27 years and there was no significant difference in mean age between males and females (p = 0.924). There was also no significant difference in mean WBC count and lymphocyte % between males and females (p > 0.05). Lung involvement according to CT-scan was ranging from 0 -80 % and the mean was 26.77 ±21.43 %; there was no significant difference in mean lung involvement between males and females (p = 0.770). The mean duration of fever at time of presentation in all enrolled patients was 6.61 ±3.60 days and it ranged from 1 to 21 days. Duration of subside of fever was ranging from 2 -25 days in all patients with a mean of 5.82 ±3.53 days; there was no significant difference in mean duration between males and females (p = 0.214). The duration needed for fever to subside was positively and significantly correlated to WBC count, the duration of fever at presentation and to the presence of diabetes mellitus (p < 0.05).

Conclusion: Longer duration of fever after diagnosis and treatment of COVID-19 can be predicted by high WBC count, longer duration of fever and presence of diabetes and those patients can be at high risk of severe complications and death.

Abstract 257 | pdf Downloads 58 PDF Downloads 160 XML Downloads 9 HTML Downloads 15


1 Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM, Bahreini E. A comprehensive review of COVID-19 characteristics. Biol Proced Online. 2020;22:19. Published 2020 Aug 4. doi:10.1186/s12575-020-00128-2
2 Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272.
3 Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40.
4 Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020;61(3):E304-E312. Published 2020 Oct 6. doi:10.15167/2421-4248/jpmh2020.61.3.1530
5 Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19 [published correction appears in Nat Rev Microbiol. 2022 Feb 23;:]. Nat Rev Microbiol. 2021;19(3):141-154. doi:10.1038/s41579-020-00459-7
6 Zalzala HH. Diagnosis of COVID-19: facts and challenges. New Microbes New Infect. 2020;38:100761. doi:10.1016/j.nmni.2020.100761
7 Kabir MA, Ahmed R, Iqbal SMA, et al. Diagnosis for COVID-19: current status and future prospects. Expert Rev Mol Diagn. 2021;21(3):269-288. doi:10.1080/14737159.2021.1894930
8 Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192-206. doi:10.1111/joim.13091
9 Tu YP, Iqbal J, O'Leary T. Sensitivity of ID NOW and RT-PCR for detection of SARS-CoV-2 in an ambulatory population. Elife. 2021;10:e65726. Published 2021 Apr 20. doi:10.7554/eLife.65726
10 Sahahjpal NS, Mondal AK, Ananth S, Jones K, Chaubey A, Kolhe R. COVID-19 diagnostic assay sensitivity: lessons for the upcoming wave or next pandemic. Future Med Chem. 2021;13(20):1713-1715. doi:10.4155/fmc-2021-0209
11 Lee CY-P, RTP L, Renia L, LFP N. Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Front Immunol. 2020;11:879.
12 Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol. 2020;9(5):e01136.
13 Jacofsky D, Jacofsky EM, Jacofsky M. Understanding Antibody Testing for COVID-19. J Arthroplasty. 2020.
14 Rabinowicz S, Leshem E, Pessach IM. COVID-19 in the Pediatric Population-Review and Current Evidence. Curr Infect Dis Rep. 2020;22(11):29. doi:10.1007/s11908-020-00739-6
15 Rathore V, Galhotra A, Pal R, Sahu KK. COVID-19 Pandemic and Children: A Review. J Pediatr Pharmacol Ther. 2020;25(7):574-585. doi:10.5863/1551-6776-25.7.574
16 Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2099-2102. doi: 10.1016/j.dsx.2020.10.029. Epub 2020 Nov 2. PMID: 33160224; PMCID: PMC7605785.
17 Zhu B, Feng X, Jiang C, et al. Correlation between white blood cell count at admission and mortality in COVID-19 patients: a retrospective study. BMC Infect Dis. 2021;21(1):574. Published 2021 Jun 14. doi:10.1186/s12879-021-06277-3
18 Carotti M, Salaffi F, Sarzi-Puttini P, et al. Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. Radiol Med. 2020;125(7):636-646. doi:10.1007/s11547-020-01237-4
19 Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15(6):335–349.
20 Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
21 Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, Song Z, Zeng Y, Shen Y, Shi Y, Zhu T, Lu H. Clinical progression of patients with COVID-19 in Shanghai, China. Journal of Infection 2020:80(5): e1–e6.
22 Mehta P, McAuley DF, Brown M, et al., Collaboration HAS . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033.